ALNYLAM PHARMACEUTICALS, INC.
No SEC Form 4 filings for $ALNY in the last 30 days.
Alnylam (ALNY) reported Q2 2026 net product revenues of $1.2B, up 74%, driven by AMVUTTRA uptake in ATTR cardiomyopathy. TTR net product revenues were $1.03B, up 89%, and the company raised AMVUTTRA run rate to over $4B annually. It lowered 2026 product guidance to $4.7B-$5.1B and revised collaboration/royalty guidance to $575M-$625M.
Alnylam Pharmaceuticals shares rose 1.7% in pre-open to $209.1 after Raymond James upgraded the stock from Outperform to Strong Buy and set a $420 price target. The upgrade followed a post–Q2 selloff tied to reduced ATTR franchise guidance. Other banks issued constructive notes. The S&P 500 and Dow were up.
AstraZeneca and Ionis’ Wainua failed to show significant cardiovascular benefit in a Phase 3 trial in ATTR-CM, an outcome analysts said likely reduces odds of filing for that indication. The article reviews other ATTR-CM programs: AstraZeneca’s cliramitug (DepleTTR-CM, ~1,200 patients), Novo Nordisk’s coramitug (CLEOPATTRA, recruiting), Alnylam’s nucresiran (TRITON-CM, completion 2030), and Intellia’s nex-z (MAGNITUDE).
Over the past 7 days, alphai's AI scored 4 news stories mentioning ALNY (ALNYLAM PHARMACEUTICALS, INC.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.
Recent ALNY coverage spans earnings, market movers and sector analysis.
Guidance cut shifts near-term revenue expectations while AMVUTTRA run-rate and first-line penetration support a longer-duration growth narrative.
The immediate catalyst is a fresh sell-side upgrade with a specific target, reframing the stock as oversold versus pipeline value.
The Wainua failure is a negative catalyst for market perception of nucresiran’s ATTR-CM prospects, increasing uncertainty around endpoint sensitivity and effect size.
Guidance cut despite strong Q2 growth signals demand normalization risk, likely pressuring near-term expectations for AMVUTTRA’s run-rate.
Guidance reduction for the core TTR franchise is likely to pressure near-term sentiment and valuation, with additional uncertainty until late-August trial data.
alphai scores every news story that mentions ALNY with an AI model for sentiment and relevance, and aggregates insider trades from ALNYLAM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alnylam (ALNY) reported Q2 2026 net product revenues of $1.2B, up 74%, driven by AMVUTTRA uptake in ATTR cardiomyopathy. TTR net product revenues were $1.03B, up 89%, and the company raised AMVUTTRA run rate to over $4B annually. It lowered 2026 product guidance to $4.7B-$5.1B and revised collaboration/royalty guidance to $575M-$625M.
7 min readAlnylam Pharmaceuticals shares rose 1.7% in pre-open to $209.1 after Raymond James upgraded the stock from Outperform to Strong Buy and set a $420 price target. The upgrade followed a post–Q2 selloff tied to reduced ATTR franchise guidance. Other banks issued constructive notes. The S&P 500 and Dow were up.
3 min readAstraZeneca and Ionis’ Wainua failed to show significant cardiovascular benefit in a Phase 3 trial in ATTR-CM, an outcome analysts said likely reduces odds of filing for that indication. The article reviews other ATTR-CM programs: AstraZeneca’s cliramitug (DepleTTR-CM, ~1,200 patients), Novo Nordisk’s coramitug (CLEOPATTRA, recruiting), Alnylam’s nucresiran (TRITON-CM, completion 2030), and Intellia’s nex-z (MAGNITUDE).
7 min readAlnylam reported Q2 2026 AMVUTTRA net product revenue of $1.01B, up 106% year over year, and total quarterly product revenue of $1.17B. Combined TTR revenue was $1.03B. Despite results, Alnylam cut 2026 TTR product revenue guidance to $4.2B-$4.5B and total net product revenue to $4.7B-$5.1B, citing normalization of second-line demand. Total Q2 revenue rose to $1.29B.
6 min readAlnylam Pharmaceuticals shares fell nearly 30% after the company lowered 2026 revenue guidance for its transthyretin amyloidosis drugs Amvuttra and Onpattro by $200 million. The estimate was cut to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion, citing normalized demand after an early launch spike. Amvuttra quarterly sales were $1.01 billion.
4 min readKirby McInerney LLP said it is investigating potential securities fraud claims involving Alnylam Pharmaceuticals (NASDAQ: ALNY). The probe follows Alnylam’s July 30, 2026 Q2 results, including lowered full-year 2026 TTR product sales guidance and a roughly $200 million reduction in projected TTR net product revenues. Alnylam shares fell about 28% to $205.48.
4 min readUS stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.
7 min readThursday, July 30, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Josh Brodsky Chief Executive Officer - Yvonne Greenstreet Chief Financial Officer - Jeff Poulton Chief Commercial Officer - Tolga Tanguler Chief Research and Development Officer - Pushkal Garg TAKEAWAYS Total Net Product Revenues -- $1.2 billion, representing 74% growth versus the second quarter of last year driven by the uptake of AMVUTTRA in ATTR cardiomyopathy.
6 min readAlnylam reported Q2 adjusted EPS of $1.84, above $1.55 consensus, while revenue rose 67% to $1.291B, below $1.323B. Amvuttra and Onpattro net product revenues were $1.012B and $18M. The company cut 2026 sales guidance to $5.275B-$5.725B from $5.30B-$5.80B, citing normalized second-line Amvuttra demand. Shares fell 29% to $202.74.
4 min readAlnylam Pharmaceuticals (ALNY) shares fell about 29% after the company reported Q2 results and lowered its full-year TTR revenue guidance. The report cited strong Q2 revenue growth and a return to profitability, including Q2 net income of $164.5 million versus a $72.2 million net loss a year earlier. The guidance change drove the reaction.
2 min read
